BSEM Overview

New Audit Firm Appointment: BioStem Technologies has appointed KPMG LLP as its new independent registered public accounting firm, replacing Marcum LLP, effective October 22, 2025, to support its growth and capital markets strategy.

Uplisting to Nasdaq: The company plans to proceed with its uplisting to the Nasdaq Capital Market following the completion of its audits for the fiscal years 2024 and 2025, aiming to enhance visibility, stock liquidity, and market valuation.

Company Overview: BioStem Technologies specializes in developing and commercializing placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method to maintain growth factors and tissue structure.

Quality Assurance: The company’s quality management system has been accredited by the American Association of Tissue Banks, ensuring compliance with Good Tissue Practices and Good Manufacturing Processes at its FDA registered facility in Pompano Beach, Florida.

CEO Stock Purchase: Jason Matuszewski, CEO of BioStem Technologies, purchased 15,500 shares on August 19, 2025, for approximately $100,000.

Transaction Details: The purchase included two transactions: 2,500 shares at $6.28 and 13,000 shares at $6.51.

Current Holdings: Following this purchase, Matuszewski now owns a total of 1.15 million shares in BioStem Technologies.

Company Performance: BioStem reported preliminary Q2 revenue of $49.3 million, indicating significant growth potential in the wound care field.

Clinical Trial Announcement: BioStem Technologies has completed patient enrollment for its clinical trial comparing BioREtain® Amnion Chorion (BR-AC) allograft to standard care for non-healing diabetic foot ulcers, with topline results expected in Q4 2025.

Market Context: Diabetic foot ulcers affect a significant portion of the diabetic population, leading to serious complications and substantial healthcare costs, estimated between $9 billion and $13 billion annually in the U.S.

Financial Performance: BioStem Technologies reported a preliminary GAAP EPS of $0.94 for Q4, exceeding expectations by $0.60, while net revenue was $102.87M, down 10.9% year-over-year but beating estimates by $16.19M.

Company Focus: The company is concentrating on advancing wound care solutions, as highlighted in their recent press release and Seeking Alpha's Quant Rating.

Earnings Release Announcement: $BSEM is set to announce its quarterly earnings on April 7th, with analysts predicting revenue of $88.4 million and earnings of $0.38 per share.

Additional Information: The article includes a disclaimer that it is not financial advice and highlights the potential for inaccuracies in the data presented.

Earnings Report Date: BioStem Technologies will report its Q2 earnings on August 12, with analysts predicting an earnings per share (EPS) of $0.270 compared to a loss of $0.200 in the same quarter last year.

Sales and Revenue Expectations: Analysts anticipate a significant sales increase of 4012.15% to $1.1 million for the quarter, with projected profits of $1.18 per share and total revenue of $180.6 million for the current fiscal year.